From DCAT Value Chain Insights (VCI)
Orchard Therapeutics, a London-headquartered biotechnology company, has appointed Mark Rothera as president and chief executive officer.
Rothera has 28 years of experience in the biopharmaceutical industry. Rothera previously served as chief commercial officer of PTC Therapeutics, a South Plainfield, New Jersey-based biopharmaceutical company. Prior to joining PTC, he served as global president of Aegerion Pharmaceuticals, a Tottori, Japan-based biopharmaceutical company, and as vice president and general manager of commercial operations at Shire’s Human Genetic Therapies division for Europe, the Middle East, and Africa.
Source: Orchard Therapeutics
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription